Drug Discovery Featured Articles & Applications

1. Injecting Cancer Killers: Intratumoral Therapy For Solid Tumors 3/5/2026

   Intratumoral injection bypasses the tumor’s physical defenses entirely, killing cancer cells and creating a personalized immune response that destroys solid tumors.

2. The Advantages Of Antibodies Over Ligands In The Alpha Emitter Era 3/5/2026

   The alpha era in radiopharmaceuticals is still being defined. The choices developers make now about delivery platforms will shape individual programs and the trajectory of the field.

3. Proteomics Tools: A Resurrection 3/4/2026

   For decades, the evolution of proteomics has lagged. Now, a resurrection is underway. New tools are dismantling limitations, signifying a maturation of systems biology.

4. Video Spotlight: Harvard's Alice Stanton On Engineering Integrated Human-Derived miBrain Organoid Models 3/3/2026

   Harvard Medical School Assistant Professor, Alice Stanton, engineered the first 3D immuno-glial-neurovascular human multicellular integrated brain (miBrain) model. In this video spotlight interview, Dr. Stanton shares her journey into science and neural organoid research.

5. Elusive Success Of CDK2: Why That May Be Changing 3/2/2026

   Cyclin-dependent kinase 2 has eluded clinical validation, but that may be changing.

6. Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage 3/2/2026

   Pre-treatment with telomerase mRNA shields human skin from radiation-induced DNA damage, reducing radiotherapy side effects.

7. Structural Biology Wages War On HIV And The Pandemics Of Tomorrow 2/27/2026

   Imagine waking up to news of another outbreak — masks, lockdowns, lives upended. But what if we could stop the next one before it starts? 

8. The Matchmaker Modality: Engineering Event-Driven Pharmacology With Induced Proximity 2/24/2026

   Induced proximity has evolved into a versatile platform with the potential to change drug discovery, but challenges still remain.

9. A State Of Stress: Developing Therapeutics Rooted In Cell Behavior 2/24/2026

   We caught up with Yerem Yeghiazarians, CEO of Soley Therapeutics, to discuss how capturing the complexity of disease requires going beyond a single target.

10. Beyond KRAS G12C: New Approaches For Drugging The Undruggable 2/20/2026

    RAS was considered among the holy grail of oncology targets, but over the past decade, this has started to change. A second wave is making its way through R&D to address current shortcomings.